The subgroup analyses showed no statistically significant interactions with users’ characteristics, including age (≥ 65 years), gender, comorbidity profile (i.e., prior CVD, HF, or CKD), or CV and baseline medication (i.e., treatment with antihypertensive drugs, insulin, sulfonylureas, GLP1-RA thiazolidinedione, and statins). Here, GLP1R is linked to chronic kidney disease.